Oxolamine
Oxolamine (SKF-9976) is an orally active antitussive. Oxolamine can inhibit CYP2B1/2. Oxolamine has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine can be used in respiratory disease research.
For research use only. We do not sell to patients.
- CAS No.: 959-14-8
- Formula: C14H19N3O
- Molecular Weight:245.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CYP2B1 |
CYP2B2 |
Oxolamine (80 mg/kg body weight initially, then 53.3 mg/kg; i.p.; 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h) shows a distinct anti-inflammatory action on the respiratory organs of guinea pigs[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Guinea pigs + non-bacterial inflammation of the respiratory tract model induced by inhalation of acrolein aerosol[4]
-
Dosage:80 mg/kg body weight initially, then 53.3 mg/kg
-
Administration:Intraperitoneal injection, 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h
-
Result:Reduced relative lung weight.
Significantly reduced inflammation levels.
Protected the pulmonary parenchyma from emphysema.
Showed anti-inflammatory effect superior to that of Phenylbutyrone.
Chemical Information
-
CAS No. 959-14-8
-
Molecular Weight 245.32
-
Formula C14H19N3O
-
SMILES
CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9(2):167-72. [Content Brief]
[2]. GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5. [Content Brief]
[3]. Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28(3):125-33. [Content Brief]
[4]. Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh). 1966;24(2):286-96. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Oxolamine Related Classifications
HY-B1717 Related Classifications
Powered by Bioz